Monitor for partnership announcements on IMM-124E (travelers diarrhea) and IMM-529 (C. diff) by 1H2027; a licensing deal could provide a material catalyst. In the near term, continued OTC sales growth in Australia and Canada supports the base case but does not justify a re-rating.
Price Chart
Executive Summary
Immuron reported 3Q FY2026 global sales of A$1.5M (+16% YoY) and YTD sales of A$5.7M (+7% YoY), with Australian sales up 15% and Canadian sales more than doubling. The company has A$10.0M cash (22.5 months of operating burn) and reiterated its strategic partnering plan for clinical assets IMM-124E and IMM-529 by 1H2027. The filing is a routine investor presentation with steady but unspectacular growth.
Key Facts
- 3Q FY2026 global sales A$1.5M, +16% vs prior year
- YTD global sales A$5.7M, +7% vs prior year
- Cash position A$10.0M as of Dec 31, 2025 (22.5 months of cash used in operating activities)
- Strategic decision to partner IMM-124E and IMM-529 by 1H2027
- Projecting 2H FY26 and full-year FY26 net sales, net profit, and EBITDX to exceed prior year
Financial Impact
Revenue growth of 7-16% YoY; cash burn rate implies >2 years runway
Risk Factors
- Small market cap (~A$9.5M) with limited trading liquidity
- Clinical pipeline requires partnership for funding; delay/no deal would pressure cash
- US sales growth modest (+1% AUD; +13% USD) indicating slow market penetration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053527 |
| Document: ea0289797-6k_immuron.htm | 0001213900-26-053527 |
| Document: 0001213900-26-053527-index-headers.html | 0001213900-26-053527 |
| Document: 0001213900-26-053527-index.html | 0001213900-26-053527 |
| Document: 0001213900-26-053527.txt | 0001213900-26-053527 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9434 (+1.44%) |
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9434 (+1.22%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9434 (+1.22%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9434 (−0.59%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9434 (−3.94%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9434 (−9.29%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9434 (−20.72%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9434 (−20.72%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9434 (−24.83%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9434 (−47.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers